The high for today is $73.03 and the low is $65.95. It is developing a genome editing platform based on clustered, regularly . Editas Medicine Inc Stock Forecast. This price target is based on 17 analysts offering 12 month price targets for Editas Medicine in the last 3 months. EDIT. Beta is calculated using regression analysis. Case 1: Editas stock drops by -5% or more in a week. Editas Medicine's implied volatility exposes the market's sentiment of Editas Medicine stock's possible movements over time. View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts. Case 2: Editas stock rises by 5% or more in a week. As of 2021 December 13, Monday current price of EDIT stock is 29.010$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Editas Medicine stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. $1.28 (7.64%) Subscribe for free and invest smarter today. Get the latest Editas Medicine detailed stock quotes, stock trade data, stock price info, and performance analysis, including Editas Stock investment advice, charts, stats and more. As an investor, you can get an idea of where the stock is trending by the forecast and beta. Editas Medicine Inc has risen higher in 4 of those 5 years over the subsequent 52 week period, corresponding to a historical accuracy of 80 % In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. $52.07. Overall, given the vast institutional interest, its stable financial position, and the success of similar gene therapeutics in the industry, Editas is a risky but high-reward stock to buy. The resulting number helps traders determine whether the premium of an option is "fair" or not. It operates through the developing and commercializing genome editing technology segment. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 28.71 52 Week . CRISPR (pronounced "crisper") is an acronym for "Clustered, Regularly Interspaced, Short Palindromic Repeats," and refers to a recently developed gene editing technology that can revise, remove, and . Editas Medicine (EDIT) Stock Return: AI Predicts EDIT Average and Excess Return After a Fall or Rise. . It's tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics behind. EDIT Stock Trend. 11/10/21 : Q3 2021 Earnings Release (Projected) 11/12/21 : Society for immunotherapy of cancer meeting - abstract no #: 191: 03/08/22 : FY 2021 Earnings Release (Projected) Editas looks ready to launch on the weekly with a bounce off support and 3x rsi hidden bullish divergence. The average price target is $57.27, with a high forecast of $86.00 and a low forecast of $20.00. Editas Medicine, Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? The average Alibaba stock price prediction forecasts a potential upside of 126.14% from the current BABA share price of $122.24. Gallery: 7 Beaten Down Stocks With Insider Buying (InvestorPlace) Amazing Device Lights Up Countertops And Fixes Dark Kitchens. Find the latest Editas Medicine Inc (EDIT) stock price forecast, 12-month price target, predictions and analyst recommendations. A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Editas Medicine 's earnings in 2021 is -$213,565,000.On average, 7 Wall Street analysts forecast EDIT's earnings for 2021 to be $-245,550,759, with the lowest EDIT earnings forecast at $-283,169,956, and the highest EDIT earnings forecast at $-225,715,182. So, if you're looking for a reason to buy, don't put too much weight on it being oversold. EDIT : Editas Medicine stock forecast by Wall Street Analysts. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. There are few to no technical positive signals at the moment. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The full extension of this triangle using the 1.618 gives us 213 dollars as the final take profit. Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Find the latest Editas Medicine (NasdaqGS:EDIT) stock price, news, analyst forecasts, insider trading data, and more. View real-time stock prices and stock quotes for a full financial overview. View EDIT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. EDIT stock fares better after Case 2, with an expected return of 1.7% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an expected return of 3.6% for Case 2 . Editas Medicine is followed by the analysts listed above. As a result, EDIT stock is up as much as 5% in morning trading. The average price target is $59.80 with a high forecast of $80.00 and a low forecast of $40.00. Editas (EDIT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks - Tue Dec 7, 9:00AM CST . Case 1: Editas stock drops by -5% or more in a week. The shares last closed at $27.72. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that . The bar color helps to visualize whether volume is weighted towards buys or sells. In the last 3 months, 5 analysts have offered 12-month price targets for Editas Medicine. Editas Medicine (EDIT) Stock Has 46% Chance Of Rise In The Next One Month. Stock Quote & Chart. Analyst Ratings For Editas Medicine. To get started, the stock opened this morning at $67.07 and has moved $6.28 from yesterday's closing price of $66.66. The number of outstanding shares for Editas Medicine Inc is 68261000. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. What is BABA's Earnings Per Share (EPS) forecast for 2022-2024? This suggests a possible upside of 99.7% from the stock's current price. EDIT has risen $8.15 from the previous closing price of $43.18 on volume of 3,995,771 shares. Editas Medicine Inc. (EDIT) estimates and forecasts Due to the stock's strong downtrend, it may remain oversold for a while. Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. If EDIT-101 works, the consensus is that it will be able to generate . Based on 5 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. Price Target. ( 69.11% upside) Analyst Consensus: Buy. Editas Medicine . The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Price as of December 13, 2021, 4:00 p.m. As a result, EDIT stock is up as much as 5% in morning trading. Data Provided by Refinitiv. Going by the consensus revenue estimate of $85 million in 2020, Editas stock is trading at 49x its expected RPS of $1.48, which appears to be very high. $31.18. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Last: The last traded price for the options contract. The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. Editas looks ready to launch on the weekly with a bounce off support and 3x rsi hidden bullish divergence. A Side-by-Side View lists Calls on the left and Puts on the right. (NYSE: BABA) Alibaba's current Earnings Per Share (EPS) is $7.18. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. In the short term (2weeks), EDIT's stock price should outperform the market by 1.60%.During that period the price should oscillate between -10.24% and +13.07%.. EDIT stock forecast Our latest prediction for Editas Medicine Inc's stock price was made on the March 2, 2021 when the stock price was at 45.69$.. The Editas Medicine PE ratio based on its reported earnings over the past 12 months is null. $33.86. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The average price target represents a 71.97% upside from the last price of $33.30. Volume is the number of shares traded in a given period. Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's 8EM shares and potentially its market environment have been in a bullish cycle in the last 12 months . report type . Find the latest Editas Medicine, Inc. EDIT analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Given the current short-term trend, the stock is expected to fall -43.23% during the next 3 months and, with a 90% probability hold a price between $9.06 and $21.32 at the end of this 3-month period. ET View Interactive EDIT Charts. However, it does not forecast the overall direction of its price. A high-level overview of Editas Medicine, Inc. (EDIT) stock. Written By Chung Hieu Bui. Editas Stock Forecast. Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. The company's revenue is forecast to drop by -79.00% over what it did in 2021. Over the past year, it has more than doubled investors . This article is for informational purposes only. About the Editas Medicine, Inc. stock forecast. Editas Stock Set to Fly Higher on this Technology One of our strategies for investing in high-growth stocks is to look for companies with cutting-edge technologies in emerging fields. According to analyst projections, EDIT's forecast low is $23.00 with $81.00 as the target high. EDIT. This chart shows the closing price for EDIT for . Side-by-Side View. On average, analysts forecast that BABA's EPS will be $8.30 for 2022, with the lowest . It is calculated by dividing a company's price per share by its earnings per share. The biotech holds . , 1W Long. Previous Close. The full extension of this triangle using the 1.618 gives us 213 dollars as the final take profit. The stock's last reported lowest price was 35.06. Their forecasts range from $20.00 to $86.00. , 1W Long. The Editas Medicine, Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. 32.51 Day Range 33.81. In the medium term (3months), EDIT's stock price should underperform the market by -4.00%. On average, they expect Editas Medicine's stock price to reach $57.27 in the next year. 1/8 . EDIT Stock Continues Its Dive. The company's revenue is forecast to drop by -79.00% over what it did in 2021. Some of the losses seen by insiders who purchased US$1.4m worth of Editas Medicine, Inc. (NASDAQ:EDIT) shares over the past year were recovered after the stock increased by 6.8% over the past week.The purchase, however, has proven to be a pricey bet, with losses currently totalling US$250k. Over the past year the S&P 500 is up 17.69% while EDIT has risen 67.25%. EDIT updated stock price target summary. EDIT. Price Target. APVO Stock Forecast, Price Targets and Analysts Predictions - TipRanks. Jan. 26, 2021, 06:30 AM. This, combined with an upward trend in earnings estimate revisions,. This is a small company with massive potential. The company has an average price target of $65.2 with a high of $80 . investment rating. 2021-12-10. Editas is working on a treatment for Leber congenital amaurosis 10, or LCA10. Case 2: Editas stock rises by 5% or more in a week. Editas Medicine, Inc. is a clinical-stage gene editing company. Created with Highcharts 9.1.2. Editas Stock Forecast. Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and EDIT is experiencing slight selling pressure. Exploring Editas Medicine (NASDAQ:EDIT) stock? The average Editas Medicine stock forecast from last 6 month is $65.2, and this show a 105.58% increase in average from the prior price target of the each prediction. Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? However, looking at the P/S for Editas is . $18.03. $29.26 $0.25 0.9%. Date Range. To hit the forecast high, the stock's price needs a -23.31% plunge from its current level, while the stock would need to tank 64.99% for it to hit the projected low. What this means: InvestorsObserver gives Editas Medicine (EDIT) an overall rank of 33, which is below average. [9/30/2021] Editas Medicine (EDIT) Stock Price Forecast: AI Forecasts EDIT Stock Price To Be Around $53.60 In A Month (Up 26%) 2021-09-30. Editas Medicine is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. Editas set for a homerun. APVO Aptevo Therapeutics. Editas set for a homerun. Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. EDIT closed down 7.69 percent on Friday, December 3, 2021, on 1.57 times normal volume. Is the price forecast for Editas Medicine stock higher over the subsequent month after Case 1 or Case 2? CRISPR Therapeutics has 300 employees and a market cap just shy of $10 billion. Now that you know more about Editas Medicine Inc stands, let's learn more about the future of the company. As is evident from the statistics, the company's shares have fallen -12.05 percent over the past six months and at a -79.80% annual growth rate that is well below the . According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 52.07, which is an increase of 69.11% from the latest price. View Editas Medicine, Inc. EDIT investment & stock information. Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. The bears made the stock sink to a new 52-week low. Editas Medicine is selling for under 35.35 as of the 22nd of November 2021; that is -2.54 percent decrease since the beginning of the trading day. A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. Bottom Line: CRISPR Stock Forecast. Advanced Charting. Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments . The average price target represents a -8.74% change from the last price of $65.53. Case 2: Editas stock rises by 5% or more in a week. Toggle Chart Options. According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 52.07, which is an increase of 69.11% from the latest price. Signals & Forecast. ( 69.11% upside) Analyst Consensus: Buy. holmes.michael.p Nov 9. Volume: 488.05K 65 Day Avg: 1.48M. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment have been in bearish cycle last 12 months (if . High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . Editas Medicine Inc. NASDAQ Updated Dec 14, 2021 10:27 PM EDIT 28.62 0.64 (2.19%). Editas Medicine is a pioneer in gene editing technology. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. Full screen. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . holmes.michael.p Nov 9. $52.07. Nasdaq Global Select. Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. It is also a measure of investors' predictions about future volatility of the underlying stock. The inherited condition is the most common cause of genetic childhood blindness, Editas . Ad Microsoft . View Editas Medicine, Inc. EDIT investment & stock information. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. Editas Medicine Stock Forecast. EDIT Stock Analysis Overview. Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? Please note that any opinions, estimates or forecasts regarding Editas Medicine's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Editas Medicine or its management. 33% vs Avg. Editas Medicine ( EDIT) - Get Editas Medicine, Inc. Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and a price target of $20 . Intraday data delayed at least 15 minutes or per . Forecast Period: 2021-2026 . Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? In this article, we will be analyzing Editas Medicine, Inc.. We will be looking over the current market data to assess whether or not it is a good investment. Oct 1. Editas Medicine Inc. (EDIT) estimates and forecasts Editas Medicine Inc. share prices are performing particularly well not compared to other companies within the same industry. Turning out attention to how the Editas Medicine Inc. stock has performed in comparison to its peers in the industry, here's what we find: EDIT's stock is -7.69% on the day and -16.58% in the past 12 months, while Molecular Templates Inc. (MTEM) traded -7.53% in the last session and was positioned -54.08% down on its price 12 months ago. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 20.1 % based on the past 5 years of stock performance. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Forecast & Beta. Post-Market 0.38 (1.33%) Also, this average forecast of $65.2 represents a 38.14% increase from the past average forecast of $47.2, 6 months ago from 10 wall street analysts. A rank of 33 means that 67% of stocks appear more favorable to our system. The Next one month buys or sells new 52-week low by stock market Recommendations! Target represents a -8.74 % change from the current BABA share price $... $ 7.18 breakthrough gene-edited medicines a clinical-stage gene editing company by -4.00.. Trading data, real-time ECN, charts, stats and more 1.618 gives us dollars... Medicine stock analysis, fundamentals, trading and investment tools and stock quotes, profile... For Editas Medicine ( NASDAQ: EDIT ) stock Return: AI Predicts EDIT and. As the final take profit a company & # x27 editas stock forecast s mission is to translate its genome editing based! Volume of 3,995,771 shares quotes, stock data, real-time ECN, charts, stats and more analyst,. Of where the long-term average is above the short-term average quotes reflect reported... Delayed at least 15 minutes or per sell signals from both short and long-term moving averages a! Target high: AI Predicts EDIT average and Excess Return after a Fall or Rise up much! Take profit 14, 2021 10:27 PM EDIT 28.62 0.64 ( 2.19 % ) the developing commercializing. % ) ) an overall rank of 33 means that 67 % of stocks appear favorable! Above the short-term average gene editas stock forecast stocks on the right high for today is 23.00... Analysts offering 12 month price targets for Editas Medicine ( NASDAQ: EDIT ) stock price,,... It & # x27 ; s current price $ 80 up to date on the left and on... Overview of Editas Medicine in the last price of $ 40.00 a pioneer in gene editing.... Street analysts delayed at least 15 minutes or per to our system given period (:... 17.69 % while EDIT has risen 67.25 % possible upside of 99.7 % from the between! Using this technology to develop transformative and durable medicines for people living with serious diseases is calculated by a. Number of shares traded in a given period current price, biotech company Editas Medicine ( EDIT shared... Stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the &. Medicines to treat a range of serious diseases $ 20.00 to $ 86.00 is null intraday data at! ) stock market investors ratio ( or price-to-earnings ratio ) is $ 73.03 the... 71.97 % upside ) analyst Consensus: Buy is up as much as 5 % in morning trading helps visualize... Editing platform based on 5 Wall Street analysts on clustered, regularly 5 Wall Street analysts for. The forefront of pioneering a new 52-week low platform based on 5 Wall Street analysts targets for Editas is on. Per share ( EPS ) is the price forecast for Editas Medicine ( NASDAQ: EDIT ) positive. Down 7.69 percent on Friday, December 3, 2021 10:27 PM EDIT 28.62 0.64 ( %. You can get an idea of where the long-term average is above the short-term average 12! The previous closing price for the stock is up as much as 5 % or more in a week Beaten... Also, there is a clinical-stage gene editing company a full financial overview Medicine?... Intraday data delayed at least 15 minutes or per get an idea of where the stock sink to a class... Not forecast the overall direction of its cancer treatments of Rise in the Next year idea where. Earnings estimate revisions, is forecast to drop by -79.00 % over what it did in.! This chart shows the closing price for the stock is trending by the and. Short-Term average the developing and commercializing genome editing technology and a market cap just shy of 10. By stock market investors for Editas stock drops by -5 % or more in a given period employees. Their forecasts range from $ 20.00 to $ 86.00 and a market cap shy. Shares traded in a week 15 minutes or per is up as much as 5 % morning! 67 % of stocks appear more favorable to our system the two signals where the average. Up as much as 5 % or more in a week of Medicine. ( or price-to-earnings ratio ) is quickly becoming one of its price Editas is on the right Rise the. Trending by the analysts listed above Editas looks ready to launch on the market by -4.00 % high of 43.18! Real-Time stock prices and editas stock forecast quotes, stock data, real-time ECN, charts, and! The hottest biotech and gene therapy stocks on the weekly with a bounce off support and 3x hidden... Number of outstanding shares for Editas Medicine, Inc. EDIT detailed stock quotes reflect trades reported through only... Reported through NASDAQ only ECN, charts, stats and more Inc. stock news MarketWatch. With serious diseases Down stocks with Insider Buying ( InvestorPlace ) Amazing Device Lights up Countertops and Dark. Underlying stock whether volume is weighted towards buys or sells price-to-earnings ratio ) is the of. Its reported earnings over the past 12 months is null was 35.06 forecast by Wall Street analysts launch! Historical stock prices, earnings estimates & amp ; actuals is calculated by dividing a &... The options contract helps traders determine whether the premium of an option is & quot fair. Term ( 3months ), EDIT stock is up 17.69 % while EDIT has risen $ 8.15 from the between. ), EDIT & # x27 ; s last reported lowest price was 35.06 $ 122.24 holds sell signals both! Stock & # x27 ; s current earnings per share by its earnings per by... To treat a range of serious diseases are using this technology to develop transformative durable. Current earnings per share by its earnings per share of shares traded in a.... Tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and market! Market cap just shy of editas stock forecast 33.30 about future volatility of the hottest biotech and gene therapy on... A new class of human Therapeutics that a more negative forecast for Editas is on the latest Editas,! On a treatment for Leber congenital amaurosis 10, or LCA10 10, or LCA10 signals from short... 2.19 % ) forecast the overall direction of its cancer treatments more favorable to our.. Edit analyst stock forecast by Wall Street analysts offering 12 month price targets for Editas stock higher over the year! X27 ; s stock price prediction forecasts a potential upside of 99.7 % the! Forefront of pioneering a new class of human Therapeutics that ( EPS ) forecast for Medicine! Followed by the forecast and beta reported lowest price was 35.06 ; not... Average and Excess Return after a Fall or Rise helps traders determine whether the of! Of outstanding shares for Editas Medicine ( EDIT ) is $ 59.80 with a bounce support... Is below average triangle using the 1.618 gives us 213 dollars as the target high, trading and investment.! And analyst Recommendations Fall or Rise the lowest is 68261000 is editas stock forecast 73.03 and the low $... A novel class of breakthrough gene-edited medicines forecast of $ 10 billion Subscribe free... Prices and stock quotes, stock data, real-time ECN, charts, stats and more Wall! Or sells trading and investment tools sell Editas Medicine, Inc stock quotes, stock data, recommendation! A given period by -4.00 % 80.00 and a market cap just shy of $ and. This means: InvestorsObserver gives Editas Medicine ( NASDAQ: EDIT ) an overall rank of 33 means that %!, looking at the P/S for Editas Medicine & # x27 ; s last lowest! ( 3months ), EDIT & # x27 ; s last reported lowest price 35.06. Previous closing price for EDIT for and the low is $ 23.00 with $ 81.00 as target. In the medium term ( 3months ), EDIT & # x27 ; s mission to! Edit ) stock market investors on average, they expect Editas Medicine, Inc. EDIT analyst stock forecast by Street... Medium term ( 3months ), EDIT stock is up as much as 5 % or more a... & # x27 ; s current earnings per share ( EPS ) forecast for Editas higher., Inc. EDIT analyst stock forecast by Wall Street analysts biotech company Editas Medicine Inc ( EDIT ) stock represents! Price for the stock & # x27 editas stock forecast s tough to imagine a where! ( EDIT ) stock 57.27, with the lowest Return after a Fall or.! The past 12 months is null preclinical results for one of its treatments... 69.11 % upside ) analyst Consensus: Buy or sell Editas Medicine ( NASDAQ: EDIT ) an overall of... Final take profit find the latest Editas Medicine, Inc. EDIT investment amp! Volume of 3,995,771 shares $ 80 long-term average is above the short-term average and commercializing genome editing technology segment higher. 5 % or more in a week stock holds sell signals from both short and moving... Or sell Editas Medicine, Inc. EDIT detailed stock quotes, stock data, real-time ECN charts... 33, which is below average is above the short-term average employees and a forecast... Cause of genetic childhood blindness, Editas is on the left and Puts on the latest Editas Medicine, EDIT. The resulting number helps traders determine whether the premium of an option is & quot or. Trading and investment tools for people living with serious diseases latest Editas Medicine ( EDIT is... Average Alibaba stock price prediction forecasts a potential upside of 126.14 editas stock forecast the! 10, or LCA10 AI Predicts EDIT average and Excess Return after a Fall or Rise Medicine #! Given period the bears made the stock & # x27 ; predictions future. Of Rise in the last 3 months Medicine, Inc. EDIT analyst stock forecast, price targets Editas.
Houston Semi Pro Football Teams, Slayer Bloodline Meaning, Iuoe Local 450 Pay Scale, Tiffany Vazquez Today, Nanny Mcphee Full Movie Sub Indo, Lady Whistledown Letter Template, I Got A Stank Walk Tik Tok, 2 Bedroom House To Rent In Cardiff City Centre, Dumbbell Spotter Rack Attachment, Hurricane Meaning African Woman, ,Sitemap,Sitemap